(Singapore/Shanghai | February 2, 2026) HSG announced that on February 2, 2026, it officially completed the global acquisition of the business and assets related to moxifloxacin (brand name: Avelox®), a core fluoroquinolone antibiotic product, and established HANGZHOU SHANZE BIOPHARMACEUTICAL CO., LTD. (Hereinafter referred to as “ShanZeBIO“), an innovative biopharmaceutical company focused on anti-infectives, respiratory diseases and critical care, along with its parent company Ascenda Pte. Ltd., to manage this business. Under the agreement, Shanzebio and its parent company, Ascenda Pte. Ltd., acquired specific global assets related to Avelox®, including drug registration certificates, intellectual property rights, and business contracts in relevant countries and regions, laying a solid foundation for the product’s continued supply and future development in global markets.
Avelox® is a fluoroquinolone antibiotic first approved in Europe and the United States in 1999. It is currently sold in more than 100 countries worldwide in tablet or intravenous injection form and is used to treat various bacterial infections, including community-acquired pneumonia, skin infections, sinusitis, and chronic bronchitis. For more than two decades, Avelox® has enjoyed the trust of both physicians and patients, achieving widespread clinical recognition and generating substantial revenue in the Chinese market.
This acquisition marks a significant step in the implementation of ShanZeBIO’s strategic focus on core disease areas and its “dual-driven” business model. The company aims to build a leading biopharmaceutical platform focused on anti-infectives, respiratory diseases and acute/critical care. Moving forward, it will adopt a unique “mature products + innovative pipelines” business model: on the one hand, leveraging Avelox®—a mature product proven in global markets—to rapidly establish a robust cash flow and a mature commercialization platform; on the other hand, it will continue to introduce late-stage innovative products to build an R&D pipeline with long-term competitiveness.
Mr. Jin Xiaodong, Chief Executive Officer of ShanZeBIO
Mr. Jin Xiaodong was recently appointed Chief Executive Officer of ShanZeBIO. Mr. Jin Xiaodong is a highly influential and seasoned executive in China’s pharmaceutical industry, with decades of extensive experience. He has held senior management positions at several multinational pharmaceutical companies and domestic biopharmaceutical firms. Prior to joining ShanZeBIO, Mr. Jin Xiaodong worked at Pfizer China as a Business Unit General Manager, where he played a key role in building teams and fostering strategic alliances with business partners, making significant contributions to the successful transformation of several key business units.
Mr. Jin Xiaodong stated, “Avelox® is a classic product in the field of anti-infectives that has benefited more than 240 million patients worldwide1. This acquisition will not only continue the product’s mission to meet the medication needs of a vast number of patients but also serve as a key cornerstone for ShanZeBIO’s development. Leveraging HSG’s extensive investment portfolio in the healthcare sector, systematic resource allocation, and proven operational management expertise, ShanZeBIO will drive sustainable business growth through efficiency improvements and supply chain integration. More importantly, we will use this as a foundation to actively advance the introduction and integration of innovative pipelines, building a globally competitive product portfolio to provide patients with comprehensive care ranging from established therapies to innovative solutions.”
About HANGZHOU SHANZE BIOPHARMACEUTICAL CO., LTD.
ShanZeBIO is an innovative biopharmaceutical company incubated and backed by HSG. The company focuses on acute/critical care, infectious diseases, and respiratory diseases. Through a model that combines “mature product operations with the introduction of innovative R&D”, it is committed to delivering sustainable medical solutions for patients worldwide.
HSG is a private equity firm specializing in investments across three key sectors: technology, healthcare, and consumer. Since its establishment in 2005, HSG has been dedicated to identifying and nurturing innovation and entrepreneurship, investing in over 1,600 companies both domestically and internationally. Among these, many have emerged as companies with distinctive technological features, innovative business models, and high growth and development potential. To date, more than 160 of HSG’s portfolio companies have successfully gone public, and over 140 private companies have grown into unicorns. In the past 20 years, HSG has expanded from its early-stage venture capital focus to include seed-stage investing, growth-stage investing, M&A investing, new infrastructure investing, and public market investing, becoming an investment firm with full-chain, full-stage, and full-cycle investment capabilities.
